Home › Drugs › Talvey (J3055)

Talvey (talquetamab-tgvs) — HCPCS J3055

Janssen Biotech (J&J) · 3 mg/1.5 mL & 40 mg/1 mL single-dose vials · Subcutaneous injection · First-in-class GPRC5D×CD3 bispecific for R/R MM (4L+)

Talvey is the first FDA-approved GPRC5D×CD3 bispecific T-cell engager for relapsed/refractory multiple myeloma, billed under HCPCS J3055 at 0.25 mg per unit (NOT 1 mg) — a high-cost biller error trap. Two FDA-approved schedules: 0.4 mg/kg SC weekly or 0.8 mg/kg SC every 2 weeks, both with 2-step step-up dosing requiring 48-hour observation. TALVEY REMS required (sites + prescribers + pharmacies + patients). Q2 2026 Medicare reimbursement: $74.876/0.25 mg unit ($9,584.13 per 32 mg weekly maintenance dose, ASP + 6%). BOXED WARNING: CRS (~76%) and ICANS (~10%). Signature toxicities (oral, skin, nail) distinct from BCMA bispecifics.

✓ASP data:Q2 2026 (live)
✓Payer policies:verified May 2026
✓Manufacturer guide:Janssen 2026
✓FDA label:revised 2025
✓Page reviewed:

Instant Answer — the 5 things you need to bill J3055

HCPCS
J3055
1 unit = 0.25 mg (NOT 1 mg)
Route
SubQ
1–2 min · abdomen/thigh
Modifier
JZ
JW for waste (heavy patients)
Admin CPT
96401
Chemo SC, anti-neoplastic
Medicare ASP+6%
$74.876
/0.25 mg unit, Q2 2026 · $299.504/mg
HCPCS descriptor
J3055 — "Injection, talquetamab-tgvs, 0.25 mg" Permanent 4/1/24
Adult dosing — weekly
Step-up Day 1 (0.01 mg/kg) · step-up Day 4 (0.06 mg/kg) · first treatment Day 7 (0.4 mg/kg) · then 0.4 mg/kg SC weekly
Adult dosing — biweekly
Step-up Day 1 (0.01 mg/kg) · step-up Day 4 (0.06 mg/kg) · step-up Day 7 (0.4 mg/kg) · first treatment Day 10 (0.8 mg/kg) · then 0.8 mg/kg SC q2wk
Indication
R/R multiple myeloma in adults with ≥4 prior lines including PI + IMiD + anti-CD38 mAb
NDC
57894-0501-01 (3 mg / 1.5 mL) · 57894-0502-01 (40 mg / 1 mL) single-dose vials
Mechanism
GPRC5D × CD3 bispecific T-cell engager (first-in-class for GPRC5D)
Premedication
Required: dexamethasone + diphenhydramine + acetaminophen 1–3 hr before each step-up dose AND first full treatment dose
Boxed warning
CRS (~76%) + Neurologic toxicity incl. ICANS (~10%) — both life-threatening; tocilizumab on hand
REMS
TALVEY REMS required: sites + prescribers + pharmacies + patients enroll · talveyrems.com · 1-855-825-5249
FDA approval
August 9, 2023 (BLA 761343), accelerated approval; label revised 2025
Calculate patient estimate → Read full reference View 1-page cheat sheet
⚠️
BILLER ERROR TRAP — J3055 unit basis is 0.25 mg, not 1 mg. A 32 mg dose (0.4 mg/kg × 80 kg patient) bills as 128 units, NOT 32 units. Underbilling by 4× drops Q2 2026 reimbursement from ~$9,584.13 to ~$2,396 per dose. Always verify mg administered × 4 = billed units. This is the most common Talvey claim error in the first year of J3055 (eff. 4/1/24) and carries multi-thousand-dollar revenue impact per dose.
⚠️
Two FDA-approved maintenance schedules — major billing/scheduling impact. Weekly: 0.4 mg/kg SC every 7 days (~50 doses/year). Biweekly (q2wk): 0.8 mg/kg SC every 14 days (~26 doses/year). Same total annual drug volume; biweekly cuts visit count ~50% but doubles per-dose drug volume and chair time. Verify which schedule is being used on every PA submission and claim. See dosing & unit math.
Phase 1 Identify what you're billing Confirm the right code, schedule, dose, and REMS enrollment before the first claim.

GPRC5D×CD3 bispecific class FDA verified May 2026

Talvey is the first FDA-approved GPRC5D-targeted bispecific. Mechanism drives the unique toxicity profile.

Talvey (talquetamab-tgvs) binds GPRC5D on multiple myeloma plasma cells with one arm and CD3 on T cells with the other, redirecting cytotoxic T-cell activity to malignant plasma cells. Approved August 9, 2023 (BLA 761343) under accelerated approval for R/R multiple myeloma in adults who have received at least 4 prior lines of therapy including a proteasome inhibitor (PI), an immunomodulatory agent (IMiD), and an anti-CD38 monoclonal antibody (e.g., daratumumab).

How Talvey differs from BCMA bispecifics (Tecvayli, Elrexfio)

Tecvayli (teclistamab-cqyv) and Elrexfio (elranatamab-bcmm) target B-cell maturation antigen (BCMA), also expressed on plasma cells. Talvey targets GPRC5D — a receptor expressed on plasma cells and on keratinized tissue (oral mucosa, skin, nail beds). This drives Talvey's signature oral/skin/nail toxicity profile, which BCMA bispecifics do not share. Class-wide bispecific risks (CRS, ICANS, infections) apply to all three.

Class peers in the myeloma 4L+ landscape: Tecvayli (BCMA bispecific), Elrexfio (BCMA bispecific, Pfizer; not in CareCost reference yet), and Talvey (GPRC5D bispecific) all carry boxed warnings for CRS and neurologic toxicity. Sequencing between them and against CAR-T (Carvykti, Abecma) is governed by NCCN MM Guidelines and payer policy.
Anti-CD38 mAb is a hard PA prerequisite. Document prior daratumumab (Darzalex or Darzalex Faspro) or isatuximab in the chart and PA submission. PA reviewers check for all three required prior classes (PI + IMiD + anti-CD38) plus ≥4 lines.

Dosing & unit math FDA label 2025 verified May 2026

From the FDA prescribing information (BLA 761343, label revised 2025).

Critical: J3055 unit basis is 0.25 mg. Always multiply mg administered × 4 = billed units. Forgetting this drops reimbursement to one-quarter of the correct amount.

Two FDA-approved maintenance schedules

DayWeekly scheduleBiweekly (q2wk) schedule
Day 10.01 mg/kg (step-up #1)0.01 mg/kg (step-up #1)
Day 40.06 mg/kg (step-up #2)0.06 mg/kg (step-up #2)
Day 70.4 mg/kg (1st full treatment dose)0.4 mg/kg (step-up #3)
Day 10—0.8 mg/kg (1st full treatment dose)
Maintenance0.4 mg/kg SC weekly (q7d)0.8 mg/kg SC q2wk (q14d)
Annual doses~50 (after step-up cycle)~26 (after step-up cycle)
Schedule choice belongs to the prescriber. Both schedules are FDA-approved; same total annual drug volume. Biweekly cuts visit count ~50% but doubles per-dose drug volume and chair time. Some sites prefer biweekly for maintenance after the patient has tolerated the weekly induction phase. Document schedule on every PA submission — switching schedules mid-treatment may require new PA at some payers.

Worked example — first-year billing for an 80 kg patient on the weekly schedule

# Step-up cycle (Days 1, 4, 7) — required for both schedules
Step-up Day 1: 0.01 mg/kg × 80 kg = 0.8 mg = 3.2 units (J3055) = ~$239.60
Step-up Day 4: 0.06 mg/kg × 80 kg = 4.8 mg = 19.2 units = ~$1,437.62
Day 7 (1st full dose, weekly): 0.4 mg/kg × 80 kg = 32 mg = 128 units = ~$9,584.13

# Maintenance — weekly schedule, ~50 doses/year
Per dose: 32 mg = 128 units × $74.876 = ~$9,584.13
Modifier: JZ · Admin: 96401 (chemo SC)

# Year-1 totals (weekly schedule)
Total doses: ~50 (after step-up)
Total drug units billed: ~6,400 + step-up units
Total drug cost (Q2 2026 ASP+6%): ~$479,206/year before sequestration

Worked example — biweekly schedule (80 kg)

# Step-up cycle (Days 1, 4, 7) — biweekly has 3 step-ups
Step-up Day 1: 0.01 mg/kg = 0.8 mg = 3.2 units = ~$239.60
Step-up Day 4: 0.06 mg/kg = 4.8 mg = 19.2 units = ~$1,437.62
Step-up Day 7: 0.4 mg/kg = 32 mg = 128 units = ~$9,584.13
Day 10 (1st full dose): 0.8 mg/kg = 64 mg = 256 units = ~$19,168.26

# Maintenance — biweekly schedule, ~26 doses/year
Per dose: 64 mg = 256 units × $74.876 = ~$19,168.26
Modifier: JZ · Admin: 96401 (chemo SC)

# Year-1 totals (biweekly schedule)
Total doses: ~26 (after step-up)
Total drug cost (Q2 2026 ASP+6%): ~$498,374/year before sequestration

Premedication — required for step-up + first treatment dose

  • Dexamethasone 16 mg (PO or IV)
  • Diphenhydramine 50 mg (or equivalent)
  • Acetaminophen 650–1000 mg (PO)
  • Administer 1–3 hours before each step-up dose AND the first full treatment dose
  • Premeds NOT required for subsequent maintenance doses unless prior CRS
  • Bill premeds separately (J1100 dexamethasone, J1200 diphenhydramine, etc.)

Step-up dosing protocol FDA REMS verified May 2026

Step-up dosing is mandatory for both schedules — mitigates CRS by ramping the immune activation gradually.

Talvey requires step-up dosing to reduce the incidence and severity of cytokine release syndrome (CRS). The step-up cycle escalates the dose over 1–2 weeks before reaching the full treatment dose. Each step-up dose AND the first full treatment dose must be administered in a setting equipped to identify and manage CRS and neurologic toxicity (ICANS), with 48-hour monitoring post-dose.

PhaseSettingMonitoring
Step-up doses (Days 1, 4, +Day 7 biweekly)Hospital inpatient (POS 21) or 23-hr observation (POS 22) at REMS-enrolled center48-hr observation post-dose; vital signs, neuro checks, CRS grading
1st full treatment doseSame as step-up — inpatient/observation48-hr observation; tocilizumab on hand
Subsequent maintenance dosesOutpatient (POS 11/22/19/24/49) at REMS-certified siteStandard SC injection observation; outpatient management
Re-initiation after >28 day gapRestart step-up cycle in inpatient/observationSame as initial step-up
Step-up doses must be delayed if CRS ≥ Grade 2 occurs. Wait until CRS resolves to Grade 1 or less before next dose. If >28 days elapse between doses, restart the step-up cycle. Document any dose delays + CRS events on the claim and in the REMS log.
Tocilizumab (Actemra J3262) on hand for CRS rescue. Standard dosing for CRS: 8 mg/kg IV (max 800 mg). Most REMS-enrolled centers stock at least 2 doses on the unit.

NDC reference FDA NDC Directory verified May 2026

NDC (10/11-digit)VialConcentrationUse
57894-501-01 / 57894-0501-01 3 mg / 1.5 mL single-dose vial 2 mg/mL Step-up doses + low-dose maintenance for low-weight patients
57894-502-01 / 57894-0502-01 40 mg / 1 mL single-dose vial 40 mg/mL Full treatment doses for most adult patients (32–80 mg range)
Match concentration to dose. The 2 mg/mL formulation (3 mg vial) is for step-up and small doses; the 40 mg/mL formulation (40 mg vial) is for full treatment doses. They are NOT interchangeable — injection volumes differ. NDC on claim must match the actual vial used.
Vial selection example (80 kg patient, 0.4 mg/kg = 32 mg dose): 1 vial of the 40 mg vial used; ~8 mg discarded. Bill JW for the 32 units of waste (~$2,396) on a separate claim line; bill JZ for the 128 administered units. For an 80 kg patient on biweekly 0.8 mg/kg = 64 mg, two 40 mg vials are used; 16 mg waste = 64 units of JW.
Phase 2 Code the claim SC chemo admin code, JZ/JW modifiers, multiple myeloma ICD-10, and inpatient POS for step-up.

Administration codes CPT verified May 2026

SC bispecific T-cell engager — chemotherapy SC admin codes apply.

CodeDescriptionWhen to use
96401 Chemotherapy administration, subcutaneous or intramuscular; non-hormonal anti-neoplastic Primary code for Talvey. SC bispecific T-cell engager qualifies as anti-neoplastic biologic.
96372 Therapeutic, prophylactic, or diagnostic injection (specify substance or drug); SC or IM Accepted by some commercial payers; pays materially less than 96401. Verify per-payer policy.
96413 / 96365 IV admin codes NOT appropriate. Talvey is SC only.
99221–99239 Inpatient E/M codes Step-up doses requiring 48-hr inpatient observation: bill inpatient E/M for the admission separately, plus 96401 for the injection itself.
99221–99238 with G0378 Observation codes (when 23-hr observation used vs full inpatient) Some sites use observation status (POS 22) instead of inpatient (POS 21) for step-up; verify with UM.
Why chemo SC for a bispecific: CPT chemotherapy administration codes (96401–96425) apply to complex monoclonal antibody and biologic anti-neoplastic administration regardless of mechanism. Bispecific T-cell engagers like Talvey are billed under chemo admin per AMA classification — this pays materially more than 96372 therapeutic injection.

Modifiers CMS verified May 2026

JZ — required when no waste

Effective July 1, 2023, CMS requires the JZ modifier on all single-dose container claims when no drug is discarded. Talvey vials are single-dose (3 mg and 40 mg). For most adult doses where the full vial volume is used (e.g., a 12 mg dose using one 3 mg vial + 9 mg from a 40 mg vial), JZ applies to the fully-used vial. JZ is the default for most Talvey claims.

JW — discarded portion

JW reports the discarded portion of a single-dose vial. Talvey weight-based dosing produces frequent partial-vial waste because doses are calculated by exact mg/kg. Example: an 80 kg patient receiving 32 mg (0.4 mg/kg) uses one 40 mg vial and discards 8 mg — bill 32 units of JW (8 mg × 4 units/mg) on a separate claim line. One of JZ or JW must be on every J3055 claim per CMS's July 2023 single-dose container policy.

Common error: Forgetting to bill JW for partial-vial waste. CMS audits often catch this. Wasted Talvey is reimbursable but must be reported. At ~$74.876/0.25 mg unit, waste from a single 40 mg vial can exceed $2,000 in unrecovered reimbursement per dose.

Modifier 25 — same-day E/M

Use modifier 25 on the E/M code when a significant, separately identifiable evaluation and management service is performed on the same day as the injection. Routine pre-injection clinical assessment is bundled.

340B modifiers (JG, TB)

For 340B-acquired Talvey, follow your MAC's current 340B modifier policy. Janssen's billing guide does not provide 340B-specific instructions; defer to MAC LCDs.

ICD-10-CM — multiple myeloma FY2026 verified May 2026

Talvey is approved for R/R MM after ≥4 prior lines — most claims will use C90.02 (in relapse).

CodeDescriptionTalvey use
C90.00Multiple myeloma, not having achieved remissionActive disease, never achieved remission — uncommon for Talvey 4L+
C90.01Multiple myeloma in remissionNOT for active treatment claims; for follow-up only
C90.02Multiple myeloma in relapseMost common ICD-10 for Talvey claims — 4L+ patients are by definition relapsed
Indication-specific PA criteria are strict. Most payers require ICD-10 code plus documentation of: (1) ≥4 prior lines of therapy, (2) prior PI (e.g., bortezomib, carfilzomib, ixazomib), (3) prior IMiD (e.g., lenalidomide, pomalidomide), (4) prior anti-CD38 mAb (e.g., daratumumab, isatuximab), and (5) TALVEY REMS enrollment confirmation. ICD-10 alone is not sufficient.
Sequencing with other bispecifics and CAR-T: NCCN MM Guidelines list Talvey alongside Tecvayli (BCMA bispecific) and CAR-T cell therapies (Carvykti, Abecma) for the 4L+ setting. Some payers require failure of one bispecific before the other; some treat them as alternatives. Verify per-payer.

Site of care matrix — inpatient step-up vs outpatient maintenance Verified May 2026

Talvey is unique in that its early doses (step-up + first full dose) require an inpatient or 23-hour observation setting equipped to manage CRS and ICANS, while later maintenance doses can transition to standard outpatient settings. This produces a two-phase site-of-care trajectory that payers track closely.

SettingPOSClaim formPhase
Hospital inpatient21UB-04 / 837IStep-up + 1st full treatment dose (48-hr observation)
Hospital outpatient (23-hr observation)22UB-04 / 837IStep-up alternative at oncology centers with rapid-response protocols
Hospital outpatient (maintenance)22 / 19UB-04 / 837IMaintenance after first cycle (REMS-cert site)
Cancer center / Oncology ASC24CMS-1500 / 837PMaintenance (REMS-cert site)
Ambulatory infusion suite (AIC)49CMS-1500 / 837PMaintenance (REMS-cert site)
Physician oncology office11CMS-1500 / 837PStable maintenance only (REMS-cert)
Patient home12N/ANOT recommended — CRS/ICANS risk; no current home pathway
Site-of-care steerage is real for maintenance. UnitedHealthcare, Aetna, and major BCBS plans run aggressive UM that pushes Talvey maintenance out of HOPD (POS 22/19) into office (POS 11) or oncology ASC (POS 24) once the patient is past the step-up + first treatment phase, generally after the first 4–8 weeks. Step-up doses are exempt from site-of-care steering (medical necessity for inpatient/observation is documented in REMS protocol).
Common error: Submitting maintenance Talvey claims from HOPD (POS 22/19) without a current medical-necessity letter triggers payer denials after the patient has stabilized. Move to POS 11 / 24 / 49 once the patient has tolerated the first 4–8 weeks of treatment.

Claim form field mapping Janssen 2026

From Janssen Talvey HCP coding & billing guide (2026 edition).

InformationCMS-1500 boxNotes
NPI17bRendering provider (must be REMS-enrolled prescriber)
NDC qualifier + 11-digit NDC + UoM + qty24A shaded areaN4 + 57894-0501-01 or 57894-0502-01 + ML + total volume in mL
HCPCS J3055 + JZ (or JW for waste)24D (drug line)Verify mg × 4 = units before submitting
Drug units24GMultiply mg administered × 4 (e.g., 32 mg = 128 units, 64 mg = 256 units)
JW waste line (if partial vial)24D (separate line)JW units = (vial mg − mg administered) × 4
CPT 96401 (admin line)24D (admin line)Chemo SC, anti-neoplastic
ICD-1021Most commonly C90.02 (MM in relapse)
PA number23Required by all major payers
REMS enrollment indicationNotes / claim attachmentDocument TALVEY REMS site enrollment ID; some payers require attachment
Step-up dose claims need extra documentation. When billing step-up doses delivered in inpatient/observation setting, attach the inpatient E/M codes (99221–99239) on the facility claim and the 96401 + J3055 + ICD-10 on the professional claim. Coordinate facility + professional billing to avoid duplicate-billing edits.
Phase 3 Get paid REMS enrollment, payer PA with full prior-line documentation, and Janssen CarePath for the patient.

TALVEY REMS — required Janssen REMS verified May 2026

Risk Evaluation and Mitigation Strategy program. Mandatory for all Talvey administrations.

Talvey can only be administered through the TALVEY REMS program. Sites, prescribers, pharmacies, and patients all enroll separately. The REMS exists because of the boxed-warning CRS and neurologic toxicity risks, plus the need to ensure step-up dosing protocol is followed and tocilizumab is on hand.

EnrollmentWhat's required
Site (REMS-Certified Healthcare Setting)Site enrollment form; protocols for CRS/ICANS recognition + management; tocilizumab on hand; 24/7 access to inpatient or observation setting
PrescriberPrescriber enrollment form; complete REMS training module; document training completion in REMS portal
Pharmacy / dispenserREMS-certified specialty pharmacy or hospital pharmacy; verifies prescriber + site enrollment before each shipment
PatientPatient counseling at first dose; receives REMS wallet card with REMS contact info + emergency instructions

Contact & resources

  • Phone: 1-855-825-5249 (TALVEY REMS Coordinating Center)
  • Web: talveyrems.com
  • Wallet card: Patient receives at first dose; carries REMS phone + emergency CRS/ICANS instructions
  • REMS audit: Janssen audits enrollment status; non-compliant sites lose access to product
Common error — administering at non-REMS-enrolled site. Triggers REMS violation, payer recoupment, and JCAHO/state regulatory citation risk. If a patient transfers to a new site for maintenance dosing, the new site must complete REMS enrollment BEFORE the first dose.
Document REMS in chart and claim. Most payers don't yet require REMS attestation on the claim form, but UHC and several Cigna/Aetna policies are moving in that direction. Keep REMS site enrollment ID accessible for audit response.

Payer policy snapshot Reviewed May 2026

All major payers require PA + ≥4 prior lines documentation + REMS enrollment confirmation.

PayerPA?Required documentationSite-of-care UM
UnitedHealthcare
Oncology Med Coverage Policy + bispecifics policy		 Yes ≥4 prior lines (PI + IMiD + anti-CD38) + REMS enrollment + GPRC5D vs BCMA rationale (when applicable) Aggressive: Maintenance steered out of HOPD via Optum-managed program
Aetna
CPB 0975 Bispecific Antibodies for Multiple Myeloma		 Yes ≥4 prior lines + REMS enrollment + ECOG ≤2 (most policies) Yes (separate Site-of-Care policy; maintenance steered out of HOPD after step-up phase)
Cigna
Specialty Pharmacy + Medical Drug policies		 Yes ≥4 prior lines + REMS enrollment + treatment center attestation Site-of-care UM common for maintenance; step-up exempt
BCBS plans
Vary by plan		 Yes Generally aligned with NCCN MM Guidelines (bispecifics 4L+) + REMS enrollment Plan-specific; most have site-of-care steering for maintenance
Medicare LCDs
Per-MAC policy		 No formal PA On-label use (R/R MM 4L+) covered; documentation in chart Limited steerage; site-of-care decisions driven by clinical setting

Step therapy & sequencing

FDA approval requires at least 4 prior lines including PI + IMiD + anti-CD38 mAb — this functions as built-in step therapy. Beyond that, some payers require failure of one bispecific (Tecvayli or Elrexfio) before approving Talvey, while others treat the three bispecifics as alternatives. CAR-T sequencing (Carvykti, Abecma) varies by payer; some require CAR-T failure before bispecifics, others the reverse.

Sequencing trap: If a patient progresses on Tecvayli (BCMA bispecific) and the prescriber wants to switch to Talvey (GPRC5D bispecific), submit a new PA with explicit GPRC5D rationale (BCMA progression / antigen escape). UHC and Aetna policies increasingly require this rationale.

Medicare reimbursement CMS Q2 2026 (live)

Quarterly ASP from CMS Part B Drug Pricing File. Refreshes automatically each quarter.

Q2 2026 payment snapshot — J3055

Effective April 1 – June 30, 2026 · Based on 4Q25 ASP submissions

ASP + 6%
$74.876
per 0.25 mg unit (= $299.504/mg)
32 mg dose (weekly)
$9,584.13
128 units × ASP+6% (0.4 mg/kg, 80 kg)
64 mg dose (biweekly)
$19,168.26
256 units × ASP+6% (0.8 mg/kg, 80 kg)
Annualized cost (80 kg patient): Weekly schedule (~50 doses) ≈ $479,206/year (Medicare ASP+6%). Biweekly schedule (~26 doses) ≈ $498,374/year. Same total drug volume; both are very high-cost — Talvey is one of the most expensive specialty oncology biologics on a per-mg basis. After ~2% sequestration: roughly 1.7 percentage points reduction.

Coverage

No NCD specific to Talvey. Coverage falls under MAC LCDs for biologics + the generic drug-coverage framework. All MACs cover J3055 for the FDA-approved on-label indication (R/R MM after ≥4 prior lines) with appropriate ICD-10 (typically C90.02) and documentation of prior therapies and REMS enrollment.

Code history

  • Pre-April 2024: Unclassified J3490, J3590, or C9399 with NDC, dose, and invoice attached
  • J3055 — permanent code, effective April 1, 2024 ("Injection, talquetamab-tgvs, 0.25 mg")

Patient assistance — Janssen CarePath Janssen verified May 2026

  • Janssen CarePath: 1-877-CarePath (1-877-227-3728) · benefits investigation, prior authorization assistance, appeals support, copay tracking
  • Talvey Savings Program: commercial copay support; eligible commercially-insured patients (excludes Medicare, Medicaid, federal program patients) — verify current annual maximum at janssencarepath.com
  • Janssen Patient Assistance Foundation (J&J PAF): free product for uninsured / underinsured patients meeting income requirements; administered through J&J's 501(c)(3)
  • Foundations for Medicare patients: PAN Foundation, HealthWell, Leukemia & Lymphoma Society (LLS), CancerCare — verify open multiple-myeloma funds quarterly (LLS and PAN have rotating MM funds)
  • Companion drug stocking: Tocilizumab (Actemra J3262) must be on hand for CRS rescue — coordinate with pharmacy
  • Web: janssencarepath.com/patient/talvey
Need to model what a specific patient will actually pay after copay assistance, deductible, coinsurance, and OOP max? Run a CareCost Estimate — J3055 pre-loaded with both weekly and biweekly schedules.
Phase 4 Manage toxicity & fix problems CRS/ICANS protocol, signature oral/skin/nail toxicity, and the most common claim errors.

CRS & ICANS management FDA boxed warning verified May 2026

BOXED WARNING — Cytokine Release Syndrome (CRS) and Neurologic Toxicity (incl. ICANS): Both life-threatening. CRS occurs in approximately 76% of patients (most during step-up and first full dose). ICANS occurs in approximately 10%. All Talvey administrations must be in a setting equipped to identify and manage CRS and ICANS. Tocilizumab (Actemra) on hand. Patients with active CNS involvement of MM excluded.

CRS recognition & grading

  • Onset: Median 27 hours after step-up dose; range 1–7 days
  • Symptoms: Fever (most common, ≥38°C), hypotension, hypoxia, tachycardia, chills
  • Grading: ASTCT consensus grading (Grade 1–4)
  • Grade 1 (fever only): Symptomatic management, supportive care
  • Grade 2 (fever + hypotension responsive to fluids OR hypoxia on low-flow O2): Tocilizumab 8 mg/kg IV (max 800 mg)
  • Grade 3+ (fever + hypotension requiring vasopressors OR hypoxia on high-flow O2): Tocilizumab + dexamethasone + ICU; consider tocilizumab repeat doses

ICANS recognition

  • Onset: Variable; often coincident with or following CRS
  • Symptoms: Aphasia, altered mental status, seizures, focal neurologic deficits, motor weakness
  • Grading: ASTCT ICE score + clinical findings (Grade 1–4)
  • Grade 2+: Dexamethasone, neurology consult, ICU monitoring as indicated
  • Tocilizumab does NOT cross blood-brain barrier — not first-line for ICANS without concurrent CRS
Dose modification required after Grade 2+ CRS or ICANS. Hold next dose until resolution to Grade 1 or less. May require repeat step-up if >28 days elapse. Document all CRS/ICANS events in REMS log and chart for payer audit and Janssen post-marketing surveillance.

Oral, skin & nail toxicity — Talvey-specific FDA label 2025 verified May 2026

Distinct from Tecvayli/Elrexfio (BCMA bispecifics). Driven by GPRC5D expression on keratinized tissue.

GPRC5D = oral/skin/nail effects. GPRC5D is expressed on plasma cells (the therapeutic target) AND on keratinized tissues including oral mucosa, skin, and nail beds. Talvey's bispecific T-cell engagement also activates immune attack on these tissues, producing the signature toxicity profile. BCMA bispecifics (Tecvayli, Elrexfio) do NOT have this profile because BCMA is restricted to plasma cells / B-cell lineage.

Oral toxicity (~80% of patients)

  • Dysgeusia (taste alteration): Most common — metallic taste, food aversion, reduced enjoyment
  • Dry mouth (xerostomia): Reduced saliva production; impacts swallowing and dentition
  • Dysphagia: Difficulty swallowing — can impact oral nutrition intake
  • Mucositis / oral pain: Discomfort with eating, drinking, oral hygiene
  • Management: Dental hygiene protocol (soft brush, alcohol-free mouthwash), lubricating mouthwashes (Biotène, BioXtra), topical lidocaine for pain, nutrition consult, dose modification for severe cases

Skin toxicity (~62% of patients)

  • Rash: Often early in treatment; range mild macular to severe palmar-plantar erythrodysesthesia
  • Palmar-plantar erythrodysesthesia (PPE / hand-foot syndrome): Erythema, swelling, pain on palms and soles
  • Pruritus: Itching, often diffuse
  • Xerosis: Generalized skin dryness
  • Management: Emollients (urea-based), topical steroids for inflammatory rash, oral antihistamines for pruritus, dose modification for severe PPE

Nail toxicity

  • Onycholysis: Nail separation from nail bed
  • Nail discoloration: Often dark/brown bands
  • Nail dystrophy: Brittle, ridged, cracking nails
  • Management: Nail hygiene, avoid trauma, topical antifungals if secondary infection

Weight loss

Driven by oral toxicity + dysphagia + dysgeusia reducing oral intake. Median weight loss 5–10% in responders; some patients lose 15%+. Nutrition consult at baseline + monthly weights are standard. Consider supplemental nutrition (Ensure/Boost) early; PEG tube placement for severe cases.

Toxicity-driven dose modification is common. The FDA label provides specific guidance for dose holds, dose reductions, and switch from weekly to biweekly schedule based on AE severity. Document modifications in chart and on each claim (some payers track dose modifications as an outcome).

Common denials & how to fix them

Denial reasonCommon causeFix
Underbilled units (1 mg basis instead of 0.25 mg)Biller treated J3055 as 1 mg = 1 unit (the J9299/Opdivo pattern)Resubmit with units = mg administered × 4. A 32 mg dose = 128 units, NOT 32 units.
Prior lines not documentedPA submitted without ≥4 prior lines including PI + IMiD + anti-CD38Submit complete prior-treatment history with line numbers, drug names, dates, and discontinuation reasons.
REMS enrollment not on fileSite / prescriber / pharmacy not enrolled in TALVEY REMSComplete REMS enrollment at talveyrems.com. Some payers require attestation on claim or PA form.
Wrong admin code (96365 / 96413)IV admin codes billed for SC drugResubmit with 96401 (chemo SC). Talvey is SC only.
JZ/JW missingSingle-dose vial claim without modifierResubmit with JZ (no waste) or JW (partial-vial waste). Required since 7/1/2023 on every J3055 claim.
Wrong NDC format (vial-level mismatched to dose)3 mg vial NDC submitted with 32 mg doseFor doses >6 mg, use the 40 mg vial NDC (57894-0502-01). For step-up small doses, use the 3 mg vial NDC (57894-0501-01).
Site of care (HOPD) for maintenanceMaintenance Talvey administered in HOPD after first 4–8 weeks on commercial plan with site-of-care UMMove to office (POS 11), oncology ASC (POS 24), or AIC (POS 49). Submit medical necessity letter if HOPD required.
Step-up dose denied (non-inpatient setting)Step-up dose administered in routine outpatient setting without 48-hr observationREMS protocol violation. Re-submit with documentation of inpatient admission (POS 21) or 23-hr observation (POS 22) with appropriate E/M codes.
Sequencing denial (after Tecvayli failure)Talvey requested after BCMA bispecific failure without GPRC5D rationaleSubmit appeal with explicit GPRC5D rationale: BCMA antigen escape, PD on Tecvayli, NCCN guideline citation for sequencing bispecifics.

Frequently asked questions

What is the HCPCS code for Talvey?

Talvey (talquetamab-tgvs) is billed under HCPCS J3055 — "Injection, talquetamab-tgvs, 0.25 mg." Each 0.25 mg equals one billable unit, so a 32 mg dose (0.4 mg/kg × 80 kg) bills as 128 units, and a 64 mg dose (0.8 mg/kg × 80 kg) bills as 256 units. J3055 became effective April 1, 2024. Pre-April 2024, claims used unclassified J3490, J3590, or C9399 with NDC documentation.

How many units do I bill for a 32 mg Talvey dose?

Bill 128 units of J3055 for a 32 mg dose. The unit basis is 0.25 mg, so always multiply mg administered × 4 to get billed units. The most common Talvey biller error in the first year of J3055 was treating it as 1 mg = 1 unit (the J9299/Opdivo pattern), which underbills by 4× and drops Q2 2026 reimbursement from ~$9,584.13 to ~$2,396 per dose. Verify mg × 4 = units on every claim.

What administration CPT do I use for Talvey?

CPT 96401 — "Chemotherapy administration, subcutaneous or intramuscular; non-hormonal anti-neoplastic." Talvey is a complex monoclonal antibody / bispecific T-cell engager classified as anti-neoplastic. Some payers accept 96372 (therapeutic SC injection) but it pays materially less. Do NOT bill IV admin codes (96413, 96365) — Talvey is SC only.

Does Talvey require REMS?

Yes. TALVEY REMS is mandatory and separate from Janssen's other myeloma REMS programs. Sites, prescribers, pharmacies, and patients all enroll separately. Patients receive a wallet card. Phone: 1-855-825-5249; web: talveyrems.com. Document REMS enrollment in chart and on claim notes. Administering at a non-enrolled site is a REMS violation that triggers payer recoupment and JCAHO citation risk.

What is the Medicare reimbursement for J3055?

For Q2 2026, the Medicare Part B payment limit for J3055 is $74.876 per 0.25 mg unit (ASP + 6%), or $299.504 per mg. A 32 mg dose (0.4 mg/kg, 80 kg patient) reimburses at approximately $9,584.13 (128 units). A 64 mg dose (0.8 mg/kg q2wk maintenance) reimburses at approximately $19,168.26 (256 units). Annualized: ~$479,206/year on the weekly schedule (~50 doses) or ~$498,374/year on the biweekly schedule (~26 doses). Sequestration (~2%) reduces actual paid by roughly 1.7 percentage points.

What are the two Talvey dosing schedules?

Talvey is FDA-approved with two distinct maintenance schedules. Weekly: step-up Day 1 (0.01 mg/kg), step-up Day 4 (0.06 mg/kg), first treatment Day 7 (0.4 mg/kg), then 0.4 mg/kg SC weekly. Biweekly (q2wk): step-up Day 1 (0.01 mg/kg), step-up Day 4 (0.06 mg/kg), step-up Day 7 (0.4 mg/kg), first treatment Day 10 (0.8 mg/kg), then 0.8 mg/kg SC every two weeks. Schedule choice is prescriber-driven; biweekly cuts visit count ~50% but doubles per-dose drug volume and chair time. Verify schedule on every PA submission.

What are Talvey's signature toxicities?

Talvey targets GPRC5D, which is expressed on plasma cells AND on oral/skin/nail keratinized tissue. This produces signature toxicities NOT seen with BCMA bispecifics (Tecvayli, Elrexfio): oral toxicity (~80%) including dysgeusia, dry mouth, dysphagia (impacts nutrition); skin toxicity (~62%) including rash, palmar-plantar erythrodysesthesia; nail disorders; weight loss. Manage with dental hygiene protocols, lubricating mouthwashes, nutrition consult, dose modifications. Plus the bispecific class boxed warnings: CRS (~76%) and ICANS (~10%) — both life-threatening.

What setting is required for step-up doses?

Step-up doses (Days 1, 4, and Day 7 for biweekly schedule) plus the first full treatment dose require administration in a setting equipped to identify and manage CRS and ICANS. Most sites use hospital inpatient (POS 21) for 48-hour observation post-dose, or 23-hour observation (POS 22) at oncology centers with rapid-response protocols. Maintenance doses can transition to hospital outpatient (POS 22/19), oncology cancer center (POS 24), or REMS-certified physician office (POS 11). Tocilizumab (Actemra J3262) must be on hand for CRS rescue.

Reference Sources & methodology Every claim on this page is sourced. Methodology and review history below.

Source documents

  1. FDA Prescribing Information — TALVEY (talquetamab-tgvs)
    FDA-approved label, BLA 761343, revised 2025
  2. TALVEY REMS Program
    Site, prescriber, pharmacy, and patient enrollment requirements; 1-855-825-5249
  3. Janssen CarePath — Talvey HCP Coding & Billing
    Manufacturer billing guide, 2026 edition
  4. CMS — Medicare Part B Drug ASP Pricing File
    Q2 2026 quarterly file, effective April 1 – June 30, 2026
  5. NCCN Clinical Practice Guidelines in Oncology — Multiple Myeloma
    Bispecific antibody recommendations for 4L+ R/R MM
  6. UnitedHealthcare — Oncology Medication Clinical Coverage Policy
  7. Aetna CPB 0975 — Bispecific Antibodies for Multiple Myeloma
  8. Cigna — Talvey medical coverage policy
  9. FDA National Drug Code Directory
    NDC 57894-0501-01 (3 mg) and 57894-0502-01 (40 mg)
  10. SEER CanMED — HCPCS J3055 reference
  11. FDA press release — Talvey accelerated approval (Aug 2023)

About this page

We maintain this page as a living reference. Medicare ASP pricing is bound to our underlying CareCost data layer and refreshes automatically when CMS publishes new quarterly files. Coding, REMS, and policy content is reviewed at least quarterly and updated whenever a source document changes.

Found an error? Email hello@carecostestimate.com.

Refresh cadence

ElementCadenceHow it's refreshed
Medicare ASP pricingQuarterlyAuto-bound to CareCost ASP layer; updates on CMS file release.
Payer policies (UHC, Aetna, Cigna, BCBS)Semi-annualManual review against published payer policy documents.
HCPCS / CPT / modifier rulesAnnualReviewed against CMS HCPCS quarterly files, AMA CPT releases.
NDC, dosing, FDA label, REMSEvent-drivenTied to manufacturer document version + FDA label revision date + REMS program updates.
CRS/ICANS management protocolEvent-drivenFDA label + ASTCT consensus updates.

Reviewer

Pending SME review. This page is staff-authored from primary sources (FDA, CMS, Janssen, NCCN, payer documents — all linked above). Final review by the CareCost editorial team, the CareCost editorial team, is in progress. Until that review is complete, treat this as a draft reference and verify each cited source for high-stakes claims. Bispecific T-cell engagers are an evolving therapeutic class; payer policies, sequencing guidance, and REMS requirements may shift quarterly.

Change log

  • — Initial publication. ASP data: Q2 2026. Manufacturer source: Janssen CarePath HCP coding guide 2026. FDA label: 2025 revision (BLA 761343). Two FDA-approved schedules (weekly + biweekly) detailed. TALVEY REMS section. Boxed-warning CRS/ICANS protocol. Talvey-specific oral/skin/nail toxicity (GPRC5D-driven, distinct from BCMA bispecifics).

Methodology

Every claim on this page is sourced inline. Pricing reflects the current CMS Part B Drug ASP Pricing File. Payer policies are read directly from each payer's published medical/pharmacy policy documents. Indication and dosing are verified against the current FDA label revision. REMS requirements verified against the Janssen TALVEY REMS site directly. We do not paraphrase from billing-software vendor blogs.

Stop calculating Talvey copays by hand.

Pre-loaded with J3055. Real-time ASP. Both weekly and biweekly schedules. Every major copay assistance program.

Try a free Talvey estimate →